The Global Initiative for Chronic Obstructive Lung Disease (COLD) recently defined COPD as "A common preventable and treatable disease characterised by persistent airflow limitation that is typically progressive and associated with an increased chronic inflammatory response of the airways and lungs to noxious particles or gases." Despite the fact that COPD patients typically exhibit the symptoms of acute respiratory infections (productive cough, dyspnoea, etc.), there may be a number of metab...
Background/Aim Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007. However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib. Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.